What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?
Factor XIa (FXIa) may be involved in thrombus formation, but only to a lesser extent involved in haemostasis. Several novel FXIa inhibitors are under investigation, and Phase II trials demonstrated marked reduction of bleeding compared with standard treatment by factor Xa inhibitors. Asundexian is a...
Saved in:
| Main Authors: | Maki Komiyama, Moritake Iguchi, Hiromichi Wada, Takanori Ikeda, Gheorghe-Andrei Dan, Koji Hasegawa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2024-07-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2023.50 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
by: Moritake Iguchi, et al.
Published: (2023-06-01) -
A Systematic Review of Factor XI/XIa Inhibitors Versus Direct Oral Anticoagulants in Patients with Atrial Fibrillation
by: Zhengbiao Xue MS, et al.
Published: (2025-04-01) -
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients
by: Maki Komiyama, et al.
Published: (2023-04-01) -
Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction
by: Yasuhiro Hamatani, et al.
Published: (2025-02-01) -
Milvexian: An Oral, Bioavailable Factor XIa Inhibitor
by: Shyon Parsa, et al.
Published: (2024-08-01)